Paper:

RESUMEN CORTO - SHORT SUMMARY

The main objective of this study was to evaluate the Leishmania control marker (LCM) in dogs which undergo leishmaniosis treatment and its use as a possible biomarker for treatment monitoring of the disease. For this purpose, LCM was determined in 14 dogs diagnosed with Leishmaniosis before (V1) and after one month (V2) of treatment. A complete CBC, biochemical profile and clinical score were performed in all cases. A total of 11 dogs showed an improvement in clinical signs and laboratory data and 3 dogs did not respond well to the treatment. Dogs that responded well to the treatment showed a significant decrease (p< 0.001) in LCM values (medianV1=100.2 versus V2= 12.38). On the other hand, the three dogs that were non-responsive to the treatment showed no decreases in the LCM (31.71 at V1 vs 32.1 t V2). In conclusion, LCM decreases significantly after a successful treatment in canine leishmaniosis and therefore it can be considered as a biomarker for treatment monitoring in this disease.

BIBLIOGRAFÍA

1. Solano-Gallego L, Miró G, Koutinas A et al: LeishVet guidelines for the practical management of canine leishmaniosis., Parasit. Vectors. 2011; (4): 86.

2. Martínez-Subiela S, Bernal LJ, Cerón JJ: Serum concentrations of acute-phase proteins in dogs with leishmaniosis during short-term treatment. Am. J. Vet. Res. 2003; (64):1021–1026.

3.Segarra S, Miró G, Montoya A et al: Randomized, allopurinol-controlled trial of the effects of dietary nucleotides and active hexose correlated compound in the treatment of canine leishmaniosis. Vet Parasitol 2017; (239): 50–56.

EVALUATION OF THE LEISHMANIA CONTROL MARKER (LCM) FOR TREATMENT MONITORING OF CANINE LEISHMANIOSIS